Breakthrough or Bust? This Aussie Biotech's $6M Bet Could Revive the Psychedelics Industry!

The Chronic Magazine
By Anne D. WardOct 30, 2024, 4:14 pm372 ptsTop
In a notable lift for the subdued psychedelics sector, Australian biotech firm Tryptamine Therapeutics Limited (ASX: TYP) has successfully raised A$6 million in a strategic placement, marking a bright spot in an otherwise sluggish financing period. This injection of capital, priced at A$0.02 per share, is led…

Read Article Share
Share Article
- email
- twitter
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on NewsBudz

Jones Soda Co. Sells Mary Jones THC Beverage Brand 66

Verano Unveils Bodega-Style Dispensary Experience at Zen Leaf Cave Creek in Phoenix 65

Nova Scotians bought $127 worth of cannabis in 2024 as sales begin to level off 62

Federal Court Upholds Arkansas Hemp Restrictions, Contradicting Texas Governor’s Stance In Vetoing Proposed Ban In His State 61

Chicago Police Can’t Search Vehicles Based on Smell of Raw Cannabis Under New Rules 59

Half-Year Retrospective: What Has Worked and What Hasn’t in Cannabis 59

Feds Say Tourist Who Admitted To Prior Marijuana Use In Legal Places Was Denied Entry To US Over Drugs—Not Bald JD Vance Meme 57

Benzinga Chicago 2025: Event Recap 53

About NewsBudz

NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates.

Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.

Whether you're interested in policy reform, health research, cannabis business, CBD, delta 9 products or lifestyle stories, NewsBudz keeps you informed and connected. Accessible on the web and mobile, NewsBudz makes it easy to explore, read, and share cannabis news anytime, anywhere.